LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

June 28, 2006

OVERNIGHT COURIER 6/28/06

Division of Dockets Management
Food and Drug Administration
Department of Health and Human Services (HFA-305)
5630 Fishers Lane, Room 1061
Rockville, MD 20852

WITHDRAWAL OF CITIZEN PETITION 2006P-0147

Dear Sir or Madam:

Reference is made to the above-cited petition submitted on March 30, 2006 requesting that the FDA make a determination that Risperdal M Tab, 3 mg and 4 mg were not voluntarily withdrawn for safety or effectiveness reasons. On June 26, 2006, FDA notified the petitioner that the innovator firm had begun distribution of the 3 mg and 4 mg ODT products. Thus, the issue is moot and the petitioner hereby requests that the petition subject to Docket 2006P-0147 be withdrawn at this time.

Sincerely,

Robert Pollock

Robert W. Pollock
Senior Vice President

RWP/pk

cc: Martin Shimer, Office of Generic Drugs
Elizabeth Sadove, Office of Regulatory Policy

R03P6179

2006P-0147

WDL 1